EBITDA Margin (Annual)

EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues

Amicus Therapeutics, Inc. (FOLD) had EBITDA Margin of 6.75% for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$634.21M
Net Income	$-27.11M
Cost of Goods Sold	$72.93M
Gross Profit	$561.28M
Operating Expenses	$601.42M
Operating Income	$32.79M
Non-Operating Income/Expense	$-32.60M
Pre-Tax Income	$0.19M
Normalized Pre-Tax Income	$0.19M
Income after Taxes	$-27.11M
Income from Continuous Operations	$-27.11M
Consolidated Net Income/Loss	$-27.11M
Normalized Income after Taxes	$-27.11M
EBIT	$32.79M
EBITDA	$42.82M
Weighted-Average Shares Outstanding (Basic)	308.36M
Weighted-Average Shares Outstanding (Diluted)	308.36M
Earnings per Share (EPS) (Basic)	$-0.09
Earnings per Share (EPS) (Diluted)	$-0.09
Balance Sheet Financials
Current Assets	$676.17M
Property, Plant, and Equipment	$27.11M
Long-Term Assets	$273.70M
Total Assets	$949.87M
Current Liabilities	$237.83M
Long-Term Debt	$392.66M
Long-Term Liabilities	$437.80M
Total Liabilities	$675.63M
Common Equity	$274.24M
Tangible Shareholders Equity	$62.53M
Shareholders Equity	$274.24M
Common Shares Outstanding	310.85M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$33.15M
Cash Flow from Investing Activities	$-46.43M
Cash Flow from Financial Activities	$0.61M
Beginning Cash	$216.72M
End Cash	$217.32M
Increase/Decrease in Cash	$0.60M
Stock-Based Compensation	$87.41M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.84
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.59
Debt to Equity Ratio	1.43
Gross Margin	88.50%
Operating Margin	5.17%
EBIT Margin	5.17%
EBITDA Margin	6.75%
Pre-Tax Profit Margin	0.03%
Profit Margin	-4.27%
Free Cash Flow	$29.85M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.67
Inventory Turnover	0.32
Receiveable Turnover	5.50
Days Sales in Receivables	66.36
Return on Equity	-9.89%
Return on Tangible Equity	-43.36%
Return on Assets	-2.85%
Return on Investments	-4.07%
Book Value Per Share	$0.88
Free Cash Flow per Share	$0.10
Operating Cash Flow per Share	$0.11

Data from Zacks Investment Research, Inc.